Veracyte stock falls 4.64 percent as Decipher data draw focus

Published on 10/06/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veracyte stock carries a Q2 revenue base of USD 150.32 million, up 15.5 percent year over year. Eleven analysts set a Moderate Buy consensus and USD 55.78 average target.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte stock (ISIN US92337F1075) was trading at USD 45.46 on Nasdaq on October 6, 2026, down 4.64 percent during the session. The move follows fresh clinical evidence for the company's Decipher Prostate test, while the latest quarter provides a stronger operating benchmark.

Decipher adds clinical evidence

According to Veracyte on September 29, a retrospective analysis of the phase III NRG/RTOG 0815 trial found that Decipher could identify intermediate-risk prostate cancer patients more likely to benefit from short-term androgen deprivation therapy alongside radiation.

The analysis covered 395 patients with a median follow-up of 10.2 years. Patients with higher Decipher scores saw an 8 percent absolute reduction in distant metastasis at 10 years when hormone therapy was added, while the low-score group represented 44 percent of patients and showed a 1 percentage point difference.

Quarterly figures set the bar

Veracyte reported USD 150.32 million in Q2 2026 revenue, up 15.5 percent from the prior-year quarter, according to MarketBeat. Adjusted EPS reached USD 0.54 versus a USD 0.41 consensus estimate, while revenue exceeded the USD 144.59 million estimate.

The Q2 operating result matters because the company is building its growth case around recurring genomic testing demand. Veracyte's latest results also showed a clear earnings comparison: adjusted EPS rose from USD 0.44 in the year-earlier quarter to USD 0.54 in Q2 2026, according to Yahoo Finance.

Analyst target remains above price

MarketBeat reports a Moderate Buy consensus from 11 analysts, with an average 12-month price target of USD 55.78. That target lies 22.7 percent above the USD 45.46 Nasdaq price, making the valuation gap a key counterpoint to the day's 4.64 percent decline.

UBS raised its Veracyte target from USD 52.00 to USD 65.00 and kept a Buy rating in a September 9 update reported by MarketBeat. The higher target contrasts with the stock's current position below its 52-week high.

Stock trades below yearly high

VCYT's USD 45.46 price on Nasdaq was 25.4 percent below its 52-week high of USD 60.91 on October 6, 2026. The session range ran from USD 44.35 to USD 48.83, and market capitalization stood at USD 3.6 billion.